Table 2

Median time from marketing authorisation to guidance publication

All drugsCancer drugs
Marketing authorisation to SMC, months (range)7.35 (1–44)8.00 (1–29)
Marketing authorisation to NICE, months (range)21.40 (2–77)23.62 (2–46)
Marketing authorisation to STA, months (range)16.05 (4–41)25.23 (4–41)
Marketing authorisation to MTA, months (range)22.81 (2–77)20.02 (2–46)
  • MTA, multiple technology assessments; NICE, National Institute of Health and Clinical Excellence; SMC, Scottish Medicines Consortium; STA, single technology assessment.